Remove Branding Remove Hormones Remove Insulin Remove Pharmacy
article thumbnail

Why the drug pricing debate is focused on insulin

pharmaphorum

The treatment has been around for over a century but insulin has still become the centre of the ongoing discussion over pricing of pharmaceutical products. Ben Hargreaves looks at why insulin’s price is so controversial and whether this could be set to change. Insulin rationing. In the US, approximately 37.3

Insulin 130
article thumbnail

Lilly again reduces list price of Insulin Lispro Injection as latest change to affordability options

The Pharma Data

Lilly’s Insulin Lispro Injection, 100 units/mL — first introduced at half the list price of branded Humalog® (insulin lispro injection, 100 units/mL) in 2019 — will now have a 70 percent lower list price than Humalog U-100 starting January 1, 2022 Insulin Lispro Injection can be ordered through all U.S.

Insulin 52
article thumbnail

Five things to watch as the Biosimilars market heats up in 2022

pharmaphorum

Semglee (insulin glargine-yfgn) is the first biosimilar available at the retail pharmacy counter, and it obtained interchangeable status. And, manufacturers will likely pay close attention to the impact of Semglee’s interchangeable designation on the adoption of biosimilars in the retail pharmacy space.